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ranslational control at the synapse is thought to be
a key determinant of neuronal plasticity. How is
such control implemented
 
?
 
 We report that small
untranslated BC1 RNA is a speciﬁc effector of transla-
tional control both in vitro and in vivo. BC1 RNA, ex-
pressed in neurons and germ cells, inhibits a rate-limiting
step in the assembly of translation initiation complexes.
A translational repression element is contained within
the unique 3
 
 
 
 domain of BC1 RNA. Interactions of this
T
 
domain with eukaryotic initiation factor 4A and poly(A)
binding protein mediate repression, indicating that the 3
 
 
 
BC1 domain targets a functional interaction between
these factors. In contrast, interactions of BC1 RNA with
the fragile X mental retardation protein could not be docu-
mented. Thus, BC1 RNA modulates translation-dependent
processes in neurons and germs cells by directly interacting
with translation initiation factors.
 
Introduction
 
Synaptic plasticity, the input-specific change in synaptic
strength after physiological stimulation, is thought to underlie
higher brain functions such as learning and memory. Long-
term modulation of synaptic efficacy depends on the de novo
synthesis of proteins, and increasing evidence suggests that
translational control of gene expression at the synapse is re-
quired for such modulation (for reviews see Wells et al., 2000;
Job and Eberwine, 2001; Richter and Lorenz, 2002; Steward
and Schuman, 2003; Kindler et al., 2005).
Support for this model comes from several lines of inves-
tigation. Diverse types of RNA have been localized to dendrites
and, in some cases, to postsynaptic dendritic microdomains
(for reviews see Job and Eberwine, 2001; Steward and Schuman,
2003). Dendrites contain the requisite machinery to translate
mRNAs (Tiedge and Brosius, 1996; Torre and Steward, 1996),
and proteins have been shown to be synthesized on site in syn-
aptodendritic domains (Torre and Steward, 1992; Crino and
Eberwine, 1996). The synthesis of some proteins in dendrites
appears to be modulated by physiological parameters such as
neurotrophic action and trans-synaptic activity (for reviews see
Wells et al., 2000; Job and Eberwine, 2001; Richter and
Lorenz, 2002; Kindler et al., 2005). These data suggest a local
translation feedback scenario in which synaptic stimulation re-
sults in a modification of protein repertoires at the synapse,
which in turn produces a change in synaptic strength.
At the same time, the data raise fundamental questions.
How is local translational control executed? What mechanisms
are used to control translational repression and activation of
mRNAs? Recent evidence has indicated that small untranslated
BC1 RNA interacts with the translational machinery (Mud-
dashetty et al., 2002; Wang et al., 2002; West et al., 2002; Zalfa
et al., 2003). Untranslated RNAs (utRNAs), also referred to
as nonprotein-coding or nonmessenger RNAs (Brosius and
Tiedge, 2004), play diverse and important roles in the control
of gene expression at the levels of transcription, RNA process-
ing, and translation (for review see Barciszewski and Erdmann,
2003). BC1 RNA is a small utRNA that is selectively expressed
in nerve cells, where it is specifically targeted to synaptoden-
dritic neuronal microdomains (Chicurel et al., 1993; Muslimov
et al., 1997). In one scenario, BC1 RNA has been suggested
to repress protein synthesis by interacting directly with the
translation initiation apparatus (Wang et al., 2002). In a sec-
ond scenario, it has been proposed that BC1 RNA mediates
translational control indirectly by interacting with the fragile X
mental retardation protein (FMRP; Zalfa et al., 2003, 2005).
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FMRP is expressed at insufficient levels or in dysfunctional
form in the fragile X syndrome, a common form of mental retar-
dation (for review see O’Donnell and Warren, 2002). In this sec-
ond scenario, it is suggested that BC1 RNA, through its highly
structured 5
 
 
 
 domain, interacts with a subset of neuronal mRNAs
and thereby targets such mRNAs for FMRP-mediated transla-
tional repression (for review see Antar and Bassell, 2003; Zalfa
et al., 2003).
Thus, although small untranslated BC1 RNA has been
implicated in the translational control of gene expression
(Tiedge et al., 1991; Muslimov et al., 1998), the underlying
mechanism remains unresolved. In this paper, we present a
functional dissection of the BC1-mediated translational repres-
sion mechanism in vitro and in vivo. We show that the 3
 
 
 
, but
not the 5
 
 
 
, BC1 domain is repression competent. The 3
 
 
 
 BC1
domain prevents productive recruitment of the small ribosomal
subunit to the mRNA. It binds directly to eukaryotic initiation
factor (eIF) 4A and poly(A) binding protein (PABP), and func-
tional interactions with both of these initiation factors are re-
quired for effective repression. The combined results establish
BC1 RNA as a directly acting effector of translational control.
 
Results
 
BC1 RNA is a specific repressor of 
translation in 
 
Xenopus laevis
 
 oocytes
 
To examine whether BC1 RNA modulates translation in living
cells, stage VI 
 
X. laevis 
 
oocytes were coinjected with luciferase
mRNA and with titrating amounts of BC1 RNA. Luciferase ac-
tivity was used as an index for relative translational efficien-
cies. Luciferase mRNA does not contain any known FMRP
recognition motifs such as G-quartets or U-rich elements (for
review see Denman, 2003).
We determined that in 
 
X. laevis 
 
oocytes, translation of lu-
ciferase mRNA was inhibited by BC1 RNA in a concentration-
dependent manner. At 20 ng per oocyte (
 
 
 
400 nM), BC1 RNA
reduced translation efficiency by 
 
 
 
80% (Fig. 1). In contrast to
BC1, U6 RNA at the same concentration had no effect on
translation (Fig. 1 B). BC1-mediated translational repression in
 
X. laevis 
 
oocytes was not further increased after 190 min, as
compared with 70 min (Fig. 1 A). Control experiments showed
that the decrease in translational efficiency was not attributable
to degradation of luciferase mRNA: injected 
 
32
 
P-labeled lu-
ciferase mRNA remained stable in the presence of titrating
amounts of BC1 RNA under the experimental conditions used
(unpublished data). BC1 RNA also repressed translation in a
concentration-dependent manner in the rabbit reticulocyte ly-
sate (RRL) system (Fig. 1 C; Wang et al., 2002). The combined
data thus show that BC1 RNA is a translational repressor that is
effective in the nanomolar concentration range.
 
A translational repression element is 
contained in the 3
 
 
 
 BC1 domain
 
Prominent secondary structure elements naturally subdivide
BC1 RNA (152 nt) into three major domains (Rozhdestvensky
et al., 2001). The 5
 
 
 
 BC1 domain forms a stable stem-loop
structure of 74 nt. This domain harbors a dendritic targeting
element, a cis-acting element that is responsible for dendritic
transport (Muslimov et al., 1997). The 5
 
 
 
 domain is separated
by one nucleotide from a central domain of 22 uninterrupted A
residues, which in turn is followed by a unique 3
 
 
 
 BC1 domain
(55 nt). This 3
 
 
 
 domain consists of a punctuated A-rich subdo-
main and a 3
 
 
 
-terminal stem-loop structure (Rozhdestvensky
et al., 2001).
Figure 1. BC1 RNA represses translation in X. laevis oocytes. (A) 10 ng
of capped and polyadenylated luciferase mRNA was coinjected into
stage VI oocytes with increasing amounts of BC1 RNA (10 ng BC1 RNA
corresponds to  200 nM intracellular). The average luminescence signal
in the absence of BC1 RNA was assigned a relative luciferase activity
value of 1. Quantitative analysis of four experiments revealed a significant
reduction of luciferase activity in the presence of BC1 RNA (one-way anal-
ysis of variance [ANOVA], P   0.001; Scheffe’s multiple comparison post
hoc analysis [comparison with 0 nM BC1 RNA control]: ***, P   0.001).
(B) In control experiments, 400 nM BC1 or U6 RNA was coinjected with
luciferase mRNA (Luc). Luminescence was measured after 55 min. Quanti-
tative analysis of four experiments revealed a significant decrease of
luciferase activity in the presence of BC1 RNA but not in the presence of
U6 RNA (one-way ANOVA, P   0.001; Scheffe’s multiple comparison
post hoc analysis [comparison with Luc control]: ***, P   0.001). (C) For
comparison, translational repression by BC1 RNA is shown in RRL. Incor-
poration of 
35S-methionine into endogenous proteins was examined in un-
treated RRL and visualized by SDS-PAGE as described previously (Wang
et al., 2002). U6 RNA was not repression competent. Quantification is
shown for the major bands. 
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Which of these BC1 domains is responsible for transla-
tional repression? We decided to take advantage of the 
 
X.
laevis 
 
oocyte system to dissect BC1 repression competence
in vivo, again using luciferase mRNA as a programming
mRNA. Full-length BC1 RNA was used as a translational
repression standard (Fig. 1 and Fig. 2 A); U4 RNA at the
same concentration was used as a negative control (Fig. 2 A).
We next tested the 3
 
 
 
 BC1 domain and found that it re-
pressed translation as effectively as full-length BC1 RNA
(Fig. 2 A). In clear contrast, the 5
 
 
 
 BC1 domain failed to re-
press translation (Fig. 2 A). We conclude that it is the 3
 
 
 
, not
the 5
 
 
 
, BC1 domain that is responsible for BC1-mediated
translational repression.
For an in-depth functional dissection of the translational
repression mechanism used by the 3
 
 
 
 BC1 domain, we next
asked which steps in the translation pathway are the targets of
such repression. In eukaryotic translation, it is frequently the
initiation phase that is subject to regulation (for reviews see
Gingras et al., 1999; Dever, 2002). To initiate translation in the
cap-dependent mode, the 40S small ribosomal subunit, eIF1,
eIF1A, eIF3, and an eIF2–GTP–Met-tRNA
 
i
 
 complex first as-
semble to form a 43S preinitiation complex (for review see
Pestova et al., 2001). This complex is next recruited to the
mRNA to form a stable 48S initiation complex after transloca-
tion (“scanning”) to the AUG start codon. This recruitment step
is dependent on the eIF4 group of factors and is coactivated by
Figure 2. The 3  BC1 domain is repression
competent. (A) Luciferase mRNA (Luc) was
coinjected with 100 nM of small RNAs into
stage VI oocytes and incubated for 55 min.
Results from four experiments were quantified
by luminescence (one-way ANOVA, P  
0.001; Scheffe’s multiple comparison post hoc
analysis [comparison with Luc control]: **, P  
0.01; *, P   0.05). (B and C) 48S complex
formation was analyzed in the presence of the
3  (B) or the 5  (C) BC1 domain (500 nM), us-
ing capped polyadenylated  -tubulin mRNA
as a programming mRNA. (D and E) Analo-
gously, 48S complex formation was probed in
the presence of the 3  (D) or the 5  (E) BC1
domain, using uncapped polyadenylated
CSFV.NS’ mRNA as a programming mRNA. 
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PABP. Initiation factors are finally released from the 48S initi-
ation complex, and the 60S ribosomal subunit joins to form the
80S complex (for review see Pestova et al., 2001).
To establish which BC1 domains target which steps in the
translation initiation pathway, we used sucrose density gradient
centrifugation analysis for an experimental visualization of inter-
mediates along the pathway. The nonhydrolyzable GTP analogue
guanylyl imidodiphosphate (GMP-PNP) was used to visualize
48S complex formation in the RRL system (Gray and Hentze,
1994). Using capped 
 
 
 
-tubulin mRNA as a programming
mRNA, we established that the 3
 
 
 
 BC1 domain repressed assem-
bly of 48S initiation complexes (Fig. 2 B). The 3
 
 
 
 BC1 domain
reduced 48S complex formation substantially, whereas the 5
 
 
 
BC1 domain had no effect (Fig. 2 C). These results demonstrate
that the 5
 
 
 
 BC1 domain does not play a role in BC1-mediated
repression of 48S complex formation. Conversely, the 3
 
 
 
 BC1
domain is sufficient to specify such repression, and we therefore
conclude that this domain harbors a translational repression ele-
ment that effectively inhibits 48S complex assembly.
In the cap-dependent initiation pathway, the steps that re-
sult in 48S complex formation are mediated by the eIF4 family
of initiation factors and include recruitment of the 43S preiniti-
ation complex to the mRNA (i.e., binding to the 5
 
 
 
 cap) and
subsequent translocation to the initiator AUG codon. Is this
eIF4-dependent stage (an important target for regulation in eu-
karyotic translation) inhibited by the 3
 
 
 
 BC1 domain? To ad-
dress this question, we combined the sucrose density gradient
centrifugation assay mentioned in the preceding paragraph
with differential internal ribosome entry site (IRES) analysis.
Translation of various viral and cellular mRNAs is initiated on
IRESs, rather than at the 5
 
 
 
 cap as in conventional translation
(for reviews see Hellen and Sarnow, 2001; Pestova et al.,
2001). On the classical swine fever virus (CSFV) IRES, 48S
initiation complexes assemble without the need for any initia-
tion factor of the eIF4 family or PABP, although all other initi-
ation factors (as well as elongation and termination factors) are
indispensable and perform the same respective functions as in
cap-dependent translation (Pestova et al., 1998). Therefore,
translation initiated on the CSFV IRES would be refractory to
repression if the inhibition mechanism exclusively targets fac-
tors of the eIF4 group. This was indeed observed to be the case
with the 3
 
 
 
 BC1 domain: if 48S complexes were assembled on
an mRNA containing a CSFV IRES, the 3
 
 
 
 BC1 domain was
no longer an effective repressor and consequently was indistin-
guishable from the 5
 
 
 
 BC1 domain (Fig. 2, D and E). We thus
conclude that the 3
 
 
 
 BC1 domain represses translation initia-
tion by functionally targeting at least one of the factors of the
eIF4 family. Interactions with PABP are also conceivable as
the latter is known to coactivate eIF4-dependent initiation
(Kahvejian et al., 2005).
 
The 3
 
 
 
 BC1 domain mediates translational 
repression through functional 
interactions with eIF4A and PABP
 
The aforementioned results suggest that the 3
 
 
 
 BC1 domain re-
presses translation initiation by targeting eIF4–PABP–mediated
recruitment of the small ribosomal subunit to the mRNA.
Full-length BC1 RNA was previously reported to bind to
PABP and eIF4A (Muddashetty et al., 2002; Wang et al., 2002;
West et al., 2002). To establish whether interactions of the 3
 
 
 
BC1 domain with PABP and/or eIF4A form the basis for the
functional role of BC1 RNA as a repressor of translation, we
determined whether translation, repressed by the 3
 
 
 
 BC1 do-
main, could be restored by replenishing with eIF4A or PABP
or stoichiometric combinations thereof.
We used the 
 
X. laevis 
 
oocyte system for these experi-
ments. Recombinant eIF4A and PABP were coinjected with
the 3
 
 
 
 BC1 domain either individually or in combination (Fig. 3).
Luciferase activity was used as an index for relative transla-
tional efficiency; this efficiency was significantly reduced in
the presence of the 3
 
 
 
 BC1 domain. Supplementation with
eIF4A or PABP alone resulted in a moderate recovery of trans-
lation; however, this recovery failed to reach statistical signifi-
cance (Fig. 3). In contrast, 3
 
 
 
 BC1–mediated repression could
be overcome by concurrent titration with eIF4A and PABP in
stoichiometric ratio (Fig. 3). At 100 nM of both factors, transla-
tional efficiency was restored to 87% of nonrepressed levels.
(We presume that some of the injected RNA is chaperoned in
living cells, i.e., is not functionally available, thus resulting in a
lower requirement for rescue proteins relative to repressor.)
Higher concentrations of eIF4A and PABP resulted in overti-
tration, i.e., failure to restore translational efficiency (Kahve-
jian et al., 2005). eIF4A and PABP are expressed at rather low
levels in stage VI 
 
X. laevis 
 
oocytes, unlike ribosomes, eIF4G,
ePAB, and other factors that are more abundant (Audet et al.,
1987; Zelus et al., 1989; Stambuk and Moon, 1992; Keiper and
Rhoads, 1999; Voeltz et al., 2001). Although it remains to be
established whether the same two factors are also limiting at
the synapse, similarities in translational control mechanisms
have been noted between oocytes and neuronal microdomains
(Richter, 2000). On the other hand, the target of translational
repression does not necessarily have to be limiting as long as
Figure 3. Translation in X. laevis oocytes, repressed by the 3  BC1 domain,
is restored by joint replenishment with eIF4A and PABP. Luciferase mRNA
(Luc) was coinjected into stage VI oocytes with  400 nM 3  BC1 domain,
100 nM eIF4A, and/or 100 nM PABP. Luminescence was measured after
1 h. Only replenishment with eIF4A and PABP in combination restored 3 
BC1–repressed translation to a level that was statistically indistinguishable
from unrepressed translation. Quantitative analysis of four experiments is
shown (one-way ANOVA, Scheffe’s multiple comparison post hoc analysis,
***, P   0.001). The observed differences among 3  BC1, 3  BC1  
eIF4A, and 3  BC1   PABP were not statistically significant. 
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the local concentration of the repressor is sufficiently high, as
is the case with BC1 RNA (Chicurel et al., 1993).
The combined results directly support the notion that the
molecular basis for BC1-mediated translational repression is a
dual interaction of the 3
 
 
 
 BC1 domain with eIF4A and PABP.
It is therefore possible that BC1 RNA interacts with both factors
concurrently, presumably as they are contained in a complex.
 
The 3
 
 
 
 BC1 domain interacts directly 
with eIF4A and PABP
 
In view of these results, we hypothesized that direct interac-
tions of the 3
 
 
 
 BC1 domain with eIF4A and/or PABP form the
molecular basis for BC1-mediated translational repression.
Electrophoretic mobility shift assays (EMSAs) were used to
test this hypothesis.
We first examined the 5
 
 
 
 BC1 domain. Using recombi-
nant eIF4A with radiolabeled RNA, we observed a distinct
shift to lower mobility (Fig. 4 A). However, this shift was abol-
ished not only by preincubation with excess unlabeled 5
 
 
 
 BC1
RNA (homologous competition) but also by preincubation with
excess unlabeled tRNA (heterologous competition). It is there-
fore concluded that the binding of the 5
 
 
 
 BC1 domain to eIF4A
is not specific. Rather, we suggest that it is a reflection of the
general ability of eIF4A to interact with RNAs that represent
helicase substrates because of their secondary structure content
(for review see Gingras et al., 1999).
Unlike the 5
 
 
 
, the 3
 
 
 
 BC1 domain was found to produce a
specific mobility shift with eIF4A (Fig. 4 A). Homologous
competition with excess 3
 
 
 
 BC1 RNA abolished the mobility
shift; in contrast, heterologous competition with excess tRNA
did not (Fig. 4 A). These results indicate that in binding BC1
RNA, eIF4A recognizes attributes that are specific to the 3
 
 
 
BC1 domain, as opposed to double-stranded secondary confor-
mations that are found in a multitude of RNAs. We thus con-
clude that the 3
 
 
 
 BC1 domain interacts directly and specifically
with eIF4A and that this interaction prevails over the more gen-
eral interactions of eIF4A with RNAs featuring secondary
structure elements.
Because restoration of BC1-repressed translation re-
quires PABP in addition to eIF4A and because we have shown
that the 3
 
 
 
 BC1 domain by itself is sufficient to express BC1
repression competence, we sought to determine whether the 3
 
 
 
BC1 domain also bound directly to PABP. Fig. 4 B shows that
this is indeed the case. Although PABP did not bind to the 5 
BC1 domain, the protein produced a specific mobility shift
with the 3  BC1 domain. This shift was abolished by competi-
tion with excess unlabeled 3  BC1 RNA but not with excess
U4 RNA (Fig. 4 B).
We conclude that the 3  BC1 domain, most likely by
virtue of its punctuated A-rich region, displays specific
binding activity toward PABP. Is the 3  BC1 domain recog-
nized by eIF4A and PABP at the same time, or is binding to
these factors mutually exclusive (e.g., alternating)? EMSA
analysis revealed that the simultaneous presence of eIF4A
and PABP produced a larger shift (i.e., to lower mobility)
than the presence of either factor alone (Fig. 4 C). These
data indicate that the 3  BC1 domain can interact with both
factors simultaneously.
Figure 4. The 3  BC1 domain binds specifically to eIF4A and PABP. EMSA experiments were performed with 
32P-labeled 5  or 3  BC1 domains. (A) BC1
domains were incubated with eIF4A in the absence or presence of unlabeled competitor RNAs. Note that the 5  BC1 domain produced a shift with eIF4A
that was abolished by unlabeled tRNAs. (B) BC1 domains were incubated with an NH2-terminal segment of PABP (aa 1–182) in the absence or presence
of unlabeled competitor RNAs. (C) When used in combination, eIF4A and PABP produced a more substantial mobility shift with the 3  BC1 domain than
did either factor alone, indicating that both factors can bind simultaneously. (D) A PABP segment containing RRM 1/2 but not a PABP segment containing
RRM 3/4 or a PABP segment containing the COOH-terminal domain produced mobility shifts with BC1 RNA (left half of gel) and with the 3  BC1 domain
(right half of the gel). Incubation was performed in the presence of 5 mg/ml heparin, followed by RNase T1 digestion (Muddashetty et al., 2002).
Omission of heparin/T1 resulted in a weak shift of BC1 RNA by PABP (RRM 3/4), suggesting binding competence of lower affinity and/or specificity of
this domain (not depicted).JCB • VOLUME 171 • NUMBER 5 • 2005 816
PABP contains four RNA recognition motif (RRM) do-
mains that mediate RNA binding (for review see Sachs and
Varani, 2000). A PABP segment containing the NH2-terminal
domains RRM 1 and 2 has been reported to bind to polyadenyl-
ate RNA effectively; however, RRM 3/4 also displays strong
RNA binding activity, although presumably mostly to RNA se-
quences other than poly(A) (Burd et al., 1991; Kuhn and Pieler,
1996; Deo et al., 1999). We therefore asked which PABP do-
main was responsible for BC1 recognition. EMSA analysis re-
vealed that an NH2-terminal segment containing RRM 1/2 was
as effective as full-length PABP in binding to either full-length
BC1 RNA or the 3  BC1 domain (Fig. 4 D). With full-length
BC1 RNA but much less so with the 3  BC1 domain, this NH2-
terminal PABP domain apparently formed dimers, probably re-
flecting an additional binding site provided by the central A22
domain. In contrast to the PABP NH2 terminus, neither a PABP
segment containing RRM 3/4 nor the COOH-terminal PABP
domain produced a significant mobility shift with either full-
length BC1 RNA or the 3  BC1 domain. We conclude that the
NH2-terminal, RRM 1/2–containing PABP domain is primarily
responsible for BC1 binding. It should be noted that it is
through the same domain that PABP interacts with eIF4G
(Imataka et al., 1998). In summary, our data indicate that the 3 
BC1 domain specifically interacts with eIF4A and with the
NH2-terminal domain of PABP. We suggest that these interac-
tions underlie BC1-mediated translational repression.
BC1 RNA fails to bind to FMRP
Our collective data show that BC1 translational repression
competence, residing in the 3  domain of the RNA, is medi-
ated through interactions with eIF4A and PABP. Does BC1
RNA in addition bind to FMRP to modulate translation
(Zalfa et al., 2003, 2005)? We used several approaches in our
efforts to establish whether FMRP is a bona fide BC1 binding
protein. All experiments were performed under physiological
salt conditions.
To examine BC1–FMRP interactions, we first per-
formed affinity capture assays to probe the capacity of biotin-
ylated BC1 RNA to engage 
35S-labeled FMRP. FMRP was
generated in a cell-free eukaryotic translation system to per-
mit arginine methylation, which appears to be necessary for
proper RNA binding (Denman, 2002). As positive controls,
we used biotinylated bone morphogenic protein receptor
(BMPR) mRNA and biotinylated eukaryotic elongation fac-
tor 1A (eEF1A) mRNA, both of which bind specifically to
FMRP (Sung et al., 2003). Bound and unbound fractions were
visualized by SDS-PAGE. Fig. 5 A shows that although
BMPR and eEF1A mRNAs were able to capture FMRP, BC1
RNA did not react.
To analyze binding of FMRP to BC1 RNA and reference
RNAs on a quantitative basis, we next combined solution-bind-
ing assays with affinity capture to quantify binding of cell-
free–produced FMRP to radiolabeled RNAs. Because it was
previously shown that FMRP binds selectively and with high
affinity to its own (FMR1) mRNA in vitro (Sung et al., 2000;
Schaeffer et al., 2001), we used this mRNA as a standard to
normalize all binding results (Miyashiro et al., 2003).
We confirmed that FMRP interacted with FMR1 mRNA
(Fig. 5 B) and with Cln3 mRNA, an mRNA that has indepen-
dently been established to bind to FMRP (for review see Den-
man, 2003). Scrapie PrP
c mRNA, having previously been
Figure 5. BC1 RNA does not bind specifically to FMRP. (A) Affinity capture
reactions were performed between 
35S-labeled FMRP and 1  g of biotinyl-
ated BMPR mRNA, 1  g of biotinylated eEF1A mRNA, and 1  g of biotin-
ylated BC1 RNA. (Note that on a molar basis, this amount represents  10
times more BC1 RNA than eEF1A mRNA and 15 times more BC1 RNA
than BMPR mRNA.) Full-length FMRP is indicated; asterisk marks incom-
plete or proteolytic products that were generated in the in vitro translation
reaction. Incubation in the absence of RNA was performed as a control
for nonspecific binding of FMRP to the resin. (B) A solution RNA binding
assay was performed to quantify interactions of FMRP with target RNAs. In
these experiments, FMRP was biotinylated and RNAs were 
32P labeled.
Binding of FMRP to its own mRNA (FMR1 mRNA) served as a positive con-
trol; Scrapie PrP
c mRNA was used as a negative control. Quantitative
analysis of three experiments revealed that binding of Scrapie PrP
c mRNA
to FMRP was significantly different from binding of FMR1 and Cln3 mRNA
but not from binding of BC1 RNA or partial G3BP mRNA (one-way
ANOVA, P   0.001; Scheffe’s multiple comparison post hoc analysis
[comparison with Scrapie PrP
c mRNA, negative control]: ***, P  
0.001). (C) AGESA FMRP competition assay between BMPR mRNA and
BC1 RNA. Specific FMRP–BMPR mRNA complexes were formed (lane 2,
compare with unbound BMPR mRNA in lane 1, indicated by dashed line)
and remained resistant to titration with BC1 RNA (lanes 3–5). (D) Analo-
gous AGESA FMRP competition assay between eEF1A mRNA and BC1
RNA. FMRP–eEF1A mRNA complexes were resistant to titration with BC1
RNA. (E) Affinity capture assays with FMRP1-280 and biotinylated eEF1A
mRNA or biotinylated BC1 RNA. (The amount of BC1 RNA used was
again 10 times higher than that of eEF1A mRNA.) FMRP1-280 was visual-
ized by Western blotting.BC1 RNA IN TRANSLATIONAL CONTROL • WANG ET AL. 817
identified as an mRNA that does not bind to FMRP (Sung et
al., 2000), was used as a negative control. Quantitative analysis
revealed that binding of FMRP to Scrapie PrP
c mRNA was not
significantly different from binding to BC1 RNA or to a partial
G3BP mRNA, another transcript previously identified as not
interacting with FMRP (for review see Denman, 2003). Scrapie
PrP
c mRNA, partial G3BP mRNA, and BC1 RNA did not ap-
pear to contain any determinants (such as G-quartet or U-rich
elements) that are known to be important for interactions with
FMRP (for review see Denman, 2003).
We next asked whether FMRP-bound BMRP mRNA or
eEF1A mRNA could be displaced by BC1 RNA. An agarose
gel electrophoresis assay (AGESA) was previously used to vi-
sualize binding of FMRP to target RNAs (Sung et al., 2003).
Such a shift was indeed observed with BMPR mRNA; how-
ever, titration with BC1 RNA (to  100 times a molar excess
over BMPR mRNA) failed to reverse this shift (Fig. 5 C). The
result shows that BC1 RNA, even in excess, was unable to dis-
place BMRP mRNA from FMRP. Analogous results were ob-
tained when eEF1A mRNA was used instead of BMRP mRNA
(Fig. 5 D).
The NH2-terminal domain of FMRP (FMRP1-217) contains
a Tudor-like RNA binding motif (Maurer-Stroh et al., 2003).
Because BC1 RNA did not compete with two bona fide FMRP-
interacting RNAs (which are likely to be recognized by FMRP
through central and/or COOH-terminal RNA binding domains;
for review see O’Donnell and Warren, 2002; Sung et al., 2003),
we wondered if the NH2-terminal Tudor-like FMRP domain
was able to bind BC1 RNA. Having used affinity capture as-
says to corroborate binding of BMPR and eEF1A mRNA to
full-length FMRP, we then used the same assay to probe the
binding capacity of FMRP1-280, as this fragment folds properly
and binds homoribopolymers (Adinolfi et al., 1999). As shown
in Fig. 5 E, we were unable to document binding of BC1 or
eEF1A mRNA to FMRP1-280. We are left to conclude that the
combined data do not provide any evidence for significant direct
interactions of FMRP with BC1 RNA.
Discussion
Translational control of gene expression provides a powerful
means for the spatiotemporal management of complex protein
repertoires in eukaryotic cells. Translational control has been
implicated in germ cell differentiation, developmental deci-
sions in early embryos, cellular responses to stress or other
environmental factors, and long-term plastic modulation of
neuronal synapses (for review see Gray and Wickens, 1998;
Sonenberg et al., 2000). The general biological significance of
translational control pathways thus invites the question of under-
lying molecular mechanisms that are used by cells to administer
such control.
Molecular mechanism of BC1 control
We illustrate here that in one such mechanism translational
control is exercised by a small utRNA. We show that small un-
translated BC1 RNA (DeChiara and Brosius, 1987) effectively
represses translation in the nanomolar concentration range in
vitro and in vivo. The functional relevance of small utRNAs in
the regulation of gene expression is now being increasingly rec-
ognized (for review see Barciszewski and Erdmann, 2003). For
example, microRNAs base pair with complimentary regions of
target mRNAs to silence gene expression posttranscriptionally
(for review see Barciszewski and Erdmann, 2003). BC1 RNA,
in contrast, represses translation by targeting protein factors that
are needed for effective initiation. We report that the unique 3 
domain of BC1 RNA contains a translational repression element
that is responsible for functional repression.
Translational control mechanisms described to date fall
into the two categories of mRNA-specific control (e.g., mecha-
nisms that are mediated through microRNAs) and general con-
trol (e.g., mechanisms that are mediated through modulation of
translation factors). Proteins operate as repressors in the previ-
ously described cases of general translational control (Gebauer
and Hentze, 2004). In contrast, in the general control mecha-
nism reported here, the repressor is a small utRNA.
Our data show that concerted interactions of the 3  BC1
domain with eIF4A and PABP are responsible for BC1-mediated
translational repression. This conclusion is based on results from
several experiments, including the finding that translation in
X. laevis oocytes, under repression by the 3  BC1 domain, can
only be restored by concurrent replenishment with eIF4A and
PABP in stoichiometric ratio. This result demonstrates that
dual interactions with eIF4A and PABP are required for effec-
tive BC1-mediated repression. The almost complete restoration
of translation after stoichiometric titration with eIF4A and
PABP indicates that functional interactions of BC1 RNA with
these two factors constitute the major determinants of BC1-
mediated translational repression. It appears that any functional
interactions of BC1 RNA that fall outside the eIF4A–PABP
pathway, if at all relevant, are supplemental in the context of
translational repression.
In eukaryotic translation, eIF4A and PABP cooperate in a
critical segment of the initiation pathway, the recruitment of
the small ribosomal subunit (in form of the 43S preinitiation
complex) to the initiator codon (for reviews see Gingras et al.,
1999; Pestova et al., 2001). In the cap-dependent mode and
IRES-mediated mode of the EMCV subtype (but not in the
eIF4-independent CSFV-IRES subtype), this recruitment re-
quires the RNA helicase activity of eIF4A to unwind secondary
structure in the 5  untranslated region of the mRNA. PABP
stimulates eIF4-dependent initiation by interacting with eIF4A-
containing eIF4F (Kahvejian et al., 2005).
What are the molecular interactions that determine
the eIF4A–PABP–dependent repression competence of BC1
RNA? Functional dissection revealed that the 3 , but not the 5 ,
domain is repression competent in X. laevis oocytes. Further-
more, the 3  BC1 domain inhibits 48S complex formation in
RRL. In both experimental systems, the 3  BC1 domain acted
in a fashion that was indistinguishable from full-length BC1
RNA, whereas the 5  BC1 domain proved ineffective. In con-
trast, IRES-mediated initiation of the CSFV subtype, which is
eIF4 and PABP independent, was refractory to repression by
the 3  BC1 domain. We conclude that the 3  domain of BC1
RNA is responsible for translational repression.JCB • VOLUME 171 • NUMBER 5 • 2005 818
Analogously, biochemical evidence indicates that the 3 ,
but not the 5 , domain interacts specifically with eIF4A and
PABP. Effective binding of PABP to poly(A) requires a ho-
mopolymeric stretch of at least 11 A residues (Deo et al.,
1999), with a spacing between neighboring PABP molecules of
 27 residues (Baer and Kornberg, 1980). It is therefore likely
that one molecule of PABP binds to the central A22 domain of
BC1 RNA. This possibility notwithstanding, our data show that
PABP binds to the 3  BC1 domain, an interaction that is proba-
bly mediated by the punctuated A-rich region in the 5  part of
the 3  domain. The combined evidence thus suggests a scenario
in which translational repression competence resides in the 3 
BC1 domain and is mediated by dual interactions with eIF4A
and PABP (Fig. 6). Additional contributions may be derived
from PABP–A22 interactions.
Exogenous poly(A) has been reported to reduce transla-
tional efficiency under certain conditions, presumably by se-
questering PABP (Jacobson and Favreau, 1983; Grossi de Sa et
al., 1988; Cao and Richter, 2002). However, poly(A)-dependent
repression can be rescued with PABP alone in both RRL
(Grossi de Sa et al., 1988) and X. laevis oocytes (Cao and
Richter, 2002). In addition, a mutant BC1 RNA in which central
and 3  A residues have been replaced or deleted does not bind
PABP (Muddashetty et al., 2002) but still represses translation
by  60% (Kondrashov et al., 2005). The oligo(A) mechanism
by itself is therefore unlikely to account for BC1-mediated
translational repression.
We conclude that by targeting and/or sequestering eIF4A
and PABP, the repression-competent 3  BC1 domain disrupts a
functional link between these two factors that is necessary for
efficient initiation. This interaction would be dynamic, with the
same RNA molecule interacting with numerous protein mole-
cules over time, and reversible, possibly dependent on the
phosphorylation status of interacting proteins. We do not want
to rule out a more sustained interaction with PABP as endoge-
nous BC1 RNA has been shown to interact with PABP in
RNA–protein complexes (Muddashetty et al., 2002; West et
al., 2002). Our conclusions are also consonant with previous
observations that functional eIF4A–PABP interactions, sup-
ported by eIF4G, eIF4B, and/or Paip-1 (PABP-interacting pro-
tein 1), effectively promote translation initiation (Craig et al.,
1998; Bushell et al., 2001). Our data raise the possibility, to be
addressed in future work, that eIF4G, eIF4B, and/or Paip-1
interact with BC1 RNA and functionally contribute to BC1-
mediated repression.
Our experimental results are not compatible, however,
with the model of BC1 RNA as a mediator of FMRP-depen-
dent translational repression (Zalfa et al., 2003, 2005). Using a
variety of experimental approaches, we were unable to detect
significant binding of BC1 RNA to FMRP under physiological
conditions or to document competition of BC1 RNA with bona
fide target RNAs for FMRP binding. The results shown in Fig. 5
indicate that FMRP may bind nonspecifically to various RNAs
in vitro, and FMRP binding to BC1 RNA evidently falls into
this category. However, such nonspecific binding can be
clearly distinguished from specific binding to genuine FMRP
targets such as FMR1 mRNA of eEF1A mRNA.
In addition, a specific interaction of FMRP with the 5 
BC1 domain would appear unlikely in view of the fact that
this domain has been retroposed and is thus contained in the
form of repetitive identifier elements in numerous other
RNAs (Deininger et al., 1996). Our data also agree with re-
cent work showing that, unlike kissing complex RNA, BC1
RNA is unable to displace FMRP from polyribosomes in
brain homogenates (Darnell et al., 2005). Finally, our results
clearly differentiate BC1-mediated translational repression,
which targets initiation, from FMRP-mediated repression,
which has been reported to occur on polyribosomes (Ceman
et al., 2003).
Nonetheless, the possibility that BC1 RNA and FMRP
interact indirectly (i.e., other than through direct binding) in
the implementation of translational repression cannot be for-
mally ruled out. It is noteworthy in this context that BC1-
negative animals exhibit decreased exploratory activity and
increased anxiety-related behavior (Skryabin et al., 2003;
Lewejohann et al., 2004); the converse phenotype has been
reported for FMRP-negative animals (for review see O’Don-
nell and Warren, 2002). Thus, in conclusion, the physiologi-
cal relationship between FMRP and BC1 RNA remains an
open question.
Figure 6. An interaction of the 3  BC1 domain with eIF4A and PABP is
responsible for BC1-mediated repression of translation initiation. As a
consequence of this interaction, formation of the 48S initiation complex
is inhibited. BC1 RNA, shown here targeting recruitment, may in addition
interact with one or both factors during translocation. BC1 targets (eIF4A
and PABP) are indicated by red asterisks. The 3  BC1 domain is shown in
red; the central A22 domain is directly 5  adjacent to the 3  domain. For
clarity, some factors that are part of the complex (e.g., eIF5) have been
omitted from this sketch. (Reprinted with permission from the Annual Review
of Cell and Developmental Biology, Vol. 21, 2005, by Annual Reviews,
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Translational control in germ cells and 
neurons
It has become apparent in recent years that some of the transla-
tional control mechanisms that are used by neurons are also in
place in developing germ cells (for review see Wells et al.,
2000). In developing oocytes and spermatogenic cells, various
mRNAs are kept in a translationally dormant state for extended
periods of time, analogous to synaptically localized mRNAs
that are presumed to remain translationally silent until acti-
vated (i.e., derepressed) by appropriate input (for reviews see
Wells et al., 2000; Job and Eberwine, 2001; Richter and
Lorenz, 2002). In addition to neurons, BC1 RNA is also ex-
pressed in developing germ cells in a manner compatible with a
role in translational regulation (Muslimov et al., 2002). Although
such a selective expression profile obviously rules out any
global  or “housekeeping” cellular function, we submit that
BC1 RNA operates as a translational repressor in nerve cells
and germ cells.
Translational control in these cell types is also provided
through the cytoplasmic polyadenylation mechanism. During
X. laevis oocyte maturation, the poly(A) tails of selected cyto-
plasmic polyadenylation element (CPE)–containing mRNAs are
extended to  150 nt, resulting in translational stimulation (for re-
views see Richter, 2000; Wells et al., 2000). Analogous mecha-
nisms have been shown to operate in neurons in the translational
regulation of CPE-containing dendritic and axonal mRNAs
(for review see Wells et al., 2000; Brittis et al., 2002). It is thus
conceivable that cytoplasmic polyadenylation and BC1-mediated
repression pathways are functionally intersecting.
It is nonetheless important to note that both pathways op-
erate at different levels and with different specificities. The
former by definition applies only to mRNAs bearing CPEs,
whereas the latter controls eIF4–PABP–mediated translation,
including cap-dependent translation and IRES-mediated trans-
lation using EMCV-like mechanisms. Several dendritic mRNAs
have been reported to harbor IRES elements, indicating that they
may be locally translated in a 5  end–independent manner (Pink-
staff et al., 2001; Dobson et al., 2005). Internal ribosome entry
would provide a means for independent regulation of translation
initiation in dendrites, differentiating it from the mostly cap-
dependent mode in somatic translation. Although the mode of
action of IRES elements in dendritic mRNAs remains to be
established (e.g., eIF4 dependent or not), BC1 RNA is well
suited to orchestrate such differential translational control.
With RNA having arisen much earlier than DNA, transla-
tional control has in all likelihood predated transcriptional control
as the predominant mode in the regulation of gene expression.
We posit that utRNAs have accompanied and driven the evolu-
tion of translational control, and they continue to acquire, as is
exemplified by BC1 RNA, novel functional roles in increas-
ingly specialized eukaryotic cell types.
Materials and methods
Plasmids
Plasmid pBCX607 was used to generate full-length BC1 RNA (Cheng et al.,
1996; Muslimov et al., 1997). A 75-nt 5  BC1 domain was transcribed
from plasmid p5 (75)pA, which was generated by cloning a pBCX607-
derived PCR product into the pSP64 Poly(A) vector (Promega) between the
HindIII and SacI sites. It was linearized with SacI and transcribed with SP6
RNA polymerase. A pBCX607-derived 65-nt 5  BC1 segment, previously
shown to contain a dendritic targeting element (Muslimov et al., 1997), pro-
duced results indistinguishable from the 75-nt 5  segment. A 60-nt 3 -termi-
nal segment of BC1 RNA was transcribed from plasmid pMK1, and U4 and
U6 RNAs were transcribed from plasmids pSP6-U4 and -U6, respectively,
as described previously (Tiedge et al., 1991; Muslimov et al., 1997).
BC1 segments used were thus the 5  BC1 domain, nt 1–75, and the 3 
BC1 domain, nt 93–152. The 3  BC1 domain contains 5 nt of the central
A22 stretch and 22 A residues in its punctuated A-rich region.
The following RNAs were used as FMRP targets or controls: BMPR
mRNA (available from GenBank/EMBL/DDBJ under accession no.
D16250; Suzuki et al., 1994), eEF1A mRNA (available from GenBank/
EMBL/DDBJ under accession no. M25504; Sung et al., 2003), FMR1
mRNA (available from GenBank/EMBL/DDBJ under accession no.
X69962; Sung et al., 2000), Cln3 mRNA (available from GenBank/
EMBL/DDBJ under accession no. NM_000086; Denman, 2003), Scrapie
PrP
c mRNA (available from GenBank/EMBL/DDBJ under accession no.
K02234; Sung et al., 2000), BC1 RNA (available from GenBank/EMBL/
DDBJ under accession no. M16113; DeChiara and Brosius, 1987), and
G3BP1-866 mRNA (available from GenBank/EMBL/DDBJ under accession
no. NM_198395; Denman, 2003).
Plasmid pT3LUC(pA) (Wakiyama et al., 2000) was used to gener-
ate capped and polyadenylated luciferase mRNA. Plasmid pTub-A98/
TA2 (provided by J. Brosius [Universität Münster, Münster, Germany] and
S. Kindler [Universität Hamburg, Hamburg, Germany]) was used to pro-
duce capped and polyadenylated  -tubulin mRNA (Wang et al., 2002).
A rat  -tubulin clone (available from GenBank/EMBL/DDBJ under acces-
sion no. V01227; Lemischka et al., 1981) containing a G-quartet at nt
1303–1324 was used to generate pTub-A98/TA2. Plasmid pMCG was
used to produce polyadenylated EMCV-IRES/GFP mRNA and plasmid
pCSFV(1–442).NS’(A) to produce polyadenylated CSFV-IRES/NS’ mRNA
(Wang et al., 2002).
FMRP and FMRP1-280 were produced from plasmids pFMR1-CDS
(pFMRP-22) and pFMRP-KH1, using a TNT wheat germ or RRL-coupled
transcription–translation system (Promega) as described previously (Sung
et al., 2000; Sung and Denman, 2001). In some cases, the proteins were
labeled with 
35S-methionine or biotin. Recombinant FMRP was expressed
in Escherichia coli BL21 from pET21A-FMRP and purified on Ni
2 -NTA
resin (Sung et al., 2003). Recombinant eIF4A was expressed from plas-
mid pET(His6-eIF4A) in E. coli BL21(DE3) (Pestova et al., 1996). Recombi-
nant PABP and PABP segments were generated as described previously
(Imataka et al., 1998; Khaleghpour et al., 2001). A COOH-terminal seg-
ment (aa 462–633) of PABP was generated from plasmid pGEX.PABP (aa
462–633). Analogously, an NH2-terminal segment (aa 1–182) of PABP
containing RRM 1/2 was generated from plasmid pGEX.PABP (aa 1–182),
and a central segment (aa 191–368) containing RRM 3/4 was generated
from plasmid pGEX6p2. PABP segments were expressed as GST-fusion pro-
teins and were purified on glutathione–Sepharose beads (GE Healthcare).
PABP plasmids were provided by H. Imataka and N. Sonenberg (McGill
University, Montreal, Canada), and the eIF4A plasmid was provided by
T. Pestova (State University of New York, Brooklyn, Brooklyn, NY).
X. laevis oocytes methods
Oocytes were harvested from mature female X. laevis as described previ-
ously (Williams et al., 1993). After treatment with 2 mg/ml collagenase
(type IA; Sigma-Aldrich) to remove the follicle layer, stage VI oocytes were
maintained in a saline solution (5 mM Hepes, pH 7.5, 0.1 M NaCl, 2
mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 2.5 mM sodium pyruvate, and 50
 g/ml gentamycin) at 18 C.
For translation assays in oocytes, capped and polyadenylated lu-
ciferase mRNA (6.5–10 ng in a total injection volume of 50 nl per cell)
was coinjected with varying amounts of BC1 RNA, BC1 domains, or other
small RNAs into the cytoplasm of each oocyte from groups of 20 oocytes.
After incubation, pools of five cells were homogenized for each sample
and luminescence was measured according to the manufacturer’s instruc-
tions (Roche), using a luminometer (TD-20/20; Turner Designs). For trans-
lation rescue analysis in X. laevis oocytes, capped and polyadenylated
luciferase mRNA was coinjected with 10 ng of the 3  BC1 domain, and
recombinant eIF4A and/or recombinant PABP as indicated into the cyto-
plasm of each oocyte from groups of 20 oocytes.
In vitro translation and analysis of ribosomal complexes
For in vitro translation assays, the RRL system (Ambion) was used as de-
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gation assays were used to probe 48S ribosomal complex formation ac-
cording to established protocols (Gray and Hentze, 1994; Pestova et al.,
1996). In brief, in vitro translation reaction mixtures (RRL) were preincu-
bated with 1.2 mM GMP-PNP. 5  and 3  BC1 domains were used at 600
nM. Polyadenylated  -tubulin mRNA or CSFV-IRES/NS’ mRNA was used
as a programming mRNA (
32P-labeled, 50 ng/reaction). Complexes were
resolved by centrifugation through a 5–25% sucrose density gradient in
SG buffer (20 mM Tris/HCl, pH 7.5, 100 mM KCl, 2 mM DTT, and 2 mM
magnesium acetate).
EMSA
EMSA was done as described previously (Wang et al., 2002). In brief,
32P-labeled BC1 RNA, 5  BC1, or 3  BC1 domains (50,000 cpm per re-
action,  10 ng) were preheated and then incubated with proteins (typi-
cally 0.5  g) in binding buffer (20 mM Hepes, pH 7.6, 300 mM KCl,
5 mM MgCl2, 2 mM DTT, and 5% glycerol) for 20 min at room temperature.
When indicated, heparin was used at 5 mg/ml, and optional T1 RNase
digestion was performed as described previously (Muddashetty et al.,
2002). If unlabeled competitor RNAs were used, they were preincubated
with proteins for 10 min before labeled RNAs were added to the reac-
tion. RNA–protein complexes were subsequently resolved on 5% poly-
acrylamide gels (60:1 polyacrylamide/bisacrylamide) and visualized
by autoradiography.
Binding of FMRP to target RNAs
Affinity capture assays were performed as described previously (Sung et
al., 2003). Western blotting was done with anti-FMRP mAb 2160 (Chemi-
con; Sung et al., 2003). For quantitative analyses of FMRP–RNA interac-
tions, we used a modified version of a previously described solution bind-
ing assay (Boelens et al., 1993). 
32P-labeled target RNAs, produced by in
vitro transcription, were incubated at 4 C for 1 h with  2 ng of biotinyl-
ated FMRP or an equivalent amount of mock reaction lysate in 100  l of
buffer containing 20 mM Hepes, pH 7.9, 2 mM MgCl2, 0.2% Nonidet
P-40, 70 mM NH4Cl, and 50 mg/ml yeast tRNA (Sigma-Aldrich). Bound
RNA was then captured with 10  l of SoftLink avidin resin (Promega); free
RNA was removed by three 30-column volume washes with 20 mM Tris/
HCl, pH 7.5, and 150 mM NaCl. In some cases, affinity capture washes
were performed with 150 mM KCl, with identical results. Bound RNA was
quantified by liquid scintillation counting. The percentage of FMR1 mRNA
bound was arbitrarily set to 100%, and binding of other RNAs was nor-
malized to this value.
For AGESA, recombinant FMRP and RNA were combined in a 10- l
reaction mixture containing 50 mM Tris/HCl, pH 7.0, 2 mM MgCl2, and
150 mM KCl. Competition experiments were performed by simultaneously
adding target and competitor RNAs via a mixture to FMRP in reaction
buffer. Incubations were allowed to proceed for 20 min at room tempera-
ture. FMRP–RNA complexes were resolved and visualized as described
previously (Sung et al., 2003).
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